Alle Aussendungen Politik Wirtschaft Finanzen Chronik Kultur Medien Karriere Tourismus Bundesländer

Acousia Therapeutics GmbH

https://www.acousia.com

Aussendungen

Kontaktpersonen

Acousia Therapeutics GmbH

Acousia Therapeutics Reaches 50% Patient Enrollment Milestone in Phase 2 PROHEAR Study

Tübingen, Germany (OTE) - Acousia Therapeutics GmbH announced that it has successfully enrolled 50% of patients in its ongoing Phase 2 clinical trial, the PROHEAR Study , evaluating ACOU085 (INN: bimokalner) for...

29.04.2025, 09:02:47
/
OTE0001

Acousia Therapeutics GmbH

Acousia Therapeutics to present its clinical Phase 2 PROHEAR study on hearing loss treatment candidate ACOU085 at upcoming confere

Tübingen, Germany (OTE) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, will be presenting the ACOU085 Phase 2 PROHEAR...

12.08.2024, 09:01:18
/
OTE0001

Acousia Therapeutics GmbH

Hearing loss company Acousia announces first patient enrolled in its Phase 2 PROHEAR-Study

Tübingen, Germany (ots) - Acousia Therapeutics GmbH, a Tübingen-based clinical stage biotech company focused on the enhancement and preservation of natural hearing, just announced the randomization of the first...

15.02.2024, 09:01:42
/
OTE0001

Acousia Therapeutics GmbH

Acousia Therapeutics attracts new investor on its path to make hearing loss a treatable disease

Tübingen (ots) - Acousia Therapeutics GmbH, a clinical-stage biotech company developing drug candidates against acute and chronic forms of hearing loss, proudly announces Esperante Ventures as the latest addition...

09.01.2024, 10:00:50
/
OTE0001

Acousia Therapeutics GmbH

Hearing Loss Company Acousia Therapeutics Green Lighted for Game-Changing Phase 2 Trial

Tübingen, Germany (ots) - Acousia Therapeutics, a pioneer clinical-stage biotech company focused on the development of novel drug therapies for the prevention and treatment of acute and chronic forms of hearing...